Skin reaction induced by subcutaneous injection of LH-RH analogue

• Published in: Hinyokika kiyo. Acta urologica Japonica Vol. 53; no. 10; p. 695
• Main Authors: Segawa, Naoki, Nishida, Takeshi, Hamada, Syuji, Azuma, Haruhito, Katsuoka, Yoji, Nozaki, Ken-Ichi, Tsuji, Motomu
• Format: Journal Article
• Language: Japanese
• Published: Japan 01.10.2007
• Subjects: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal - administration & dosage; Antineoplastic Agents, Hormonal - adverse effects; Gonadotropin-Releasing Hormone - analogs & derivatives; Goserelin - administration & dosage; Goserelin - adverse effects; Granuloma - etiology; Granuloma - pathology; Humans; Injections, Subcutaneous - adverse effects; Leuprolide - administration & dosage; Leuprolide - adverse effects; Male; Middle Aged; Prostatic Neoplasms - drug therapy; Skin - pathology
• ISSN: 0018-1994

Luteinizing hormone-releasing hormone agonist (LH-RH analogue) therapy, is one of the most widely used hormonal therapies. Recently, subcutaneous injection of a new long acting 3-month LHRH analogue depot has been developed. We investigated the adverse events induced by injection of an LH-RH analogue in 82 patients (median age was 75 year old, 59-87) using our questionnaire. Forty-eight and 34 cases had been administered leuprorelin acetate (LSR) and goserelin acetate (ZLA). The presentation rate of skin reaction was 8.8% (3/34) in the ZLA group and 14.6% (7/48) in the LSR group. There was no significant difference in rate of skin reaction between the LSR and ZLA group (p = 0.5113). Eight patients had induration (6 in LSR 2 in ZLA). We also present a case of subcutaneous granuloma formation at the injection site after using the three-month type preparation of leuprorelin acetate. We should be aware of the risk of skin reactions at the injection site and monitor carefully when using an LH-RH analogue.